Date: August 6, 2013
Location: Princeton Marriott (Princeton, NJ)
5:30 Networking Reception
6:30 pm Welcome by BRC Program Director Dolly Koltchev, Ph.D., and Teri Conte, Region Manager, FUJIFILM Visualsonics, Inc. , Program Begins
8:00 pm Adjourn
Cardiovascular disease includes a wide variety of conditions that, despite the advances of pharmaceutical R&D, represent still unmet medical needs. It is the leading cause of death in the developed world; therefore treatment of cardiovascular disease is currently a major focus for developing innovative programs, therapeutics and diagnostics modalities for the pharmaceutical industry. In addition, cardiotoxicity remains a major cause of concern during preclinical, clinical and post-approval withdrawal of medicines. Cardiotoxicity is observed mainly with anticancer drugs, but is also correlated with treatment with other classes of drugs, including antibiotics, antidepressants, and antipsychotics.
Development of cutting edge imaging technologies allows researchers at the world’s most prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct research in cardiovascular, cancer, neurobiology and developmental biology areas. These technologies support applications that include genetic research, phenotypic studies, drug development, biomarker validation and off-target cardiovascular effects for novel biotherapeutics. Imaging and imaging analysis have become increasingly important for evaluation of drug candidates in preclinical and clinical studies.
The program, presented by BioPharma Research Council (BRC) together with FUJIFILM, will address important questions in developing imaging biomarkers and evaluating cardiotoxicity off-target effects for preclinical and clinical studies of cardiovascular disease.
Thank You to our Partners: